Kintor Pharmaceutical Ltd

Kintor Pharmaceutical Limited is a clinical-stage novel drug developer focused on small molecules and biologic drugs for dermatology and oncology. Its product candidates include KX-826, a potential topical drug for androgenic alopecia (AGA) and acne vulgaris in phase III clinical trials, and GT20029, a topical AR-PROTAC compound for AGA and acne vulgaris in phase II clinical trials. The company is also developing ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor targeting activin receptor-like kinase-1 for metastatic hepatocellular carcinoma and solid tumours in phase I and II trials; GT1708F, a Hedgehog/SMO inhibitor for idiopathic pulmonary fibrosis and blood cancer in phase I trials; and GT0486, a PI3K/mTOR inhibitor and second-generation mTOR inhibitor for metastatic solid tumours in phase I trials. Founded in 2009, Kintor Pharmaceutical Limited is headquartered in Suzhou, the People's Republic of China.